US OptionsDetailed Quotes
BCRX240920C2000
- 4.18
- 0.000.00%
15min DelayClose Sep 13 16:00 ET
0.00High0.00Low
4.18Open4.18Pre Close0 Volume2 Open Interest2.00Strike Price0.00Turnover1355.57%IV-21.97%PremiumSep 20, 2024Expiry Date5.92Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9519Delta0.0081Gamma1.23Leverage Ratio-0.1340Theta0.0001Rho1.17Eff Leverage0.0009Vega
BioCryst Pharmaceuticals Stock Discussion
Sign in to post a comment
The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...
Jefferies analysts cited 10 possible policies that Tr...
28
6
$BioCryst Pharmaceuticals (BCRX.US)$ Reuters · 1 min ago BioCryst Pharmaceuticals- Orladeyo® (Berotralstat) Approved in Peru
$BioCryst Pharmaceuticals (BCRX.US)$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.
1
$BioCryst Pharmaceuticals (BCRX.US)$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat
1
2
$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
2
$BioCryst Pharmaceuticals (BCRX.US)$
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
1
$BioCryst Pharmaceuticals (BCRX.US)$ Still with the buy rating with a 12 PT!
1
Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
1
$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
1
2
No comment yet
Cat Burger : all the good shares on his side
Simon 5183 : The lower Trump's stock price, the greater the pressure from Financial Street, which means that Trump's chances of winning are greater.
dookiro : Will interest fed rate drop drastically if Trump were to win?
D3VIN dookiro : no
Mr Neitaniel :
View more comments...